Nobuya Akizuki1, Ken Shimizu2, Mariko Asai3, Tomohito Nakano4, Takuji Okusaka5, Kazuaki Shimada6, Hironobu Inoguchi7, Masatoshi Inagaki8, Maiko Fujimori9, Tatsuo Akechi10, Yosuke Uchitomi11. 1. Psycho-Oncology Division, Chiba Cancer Center, Chiba. 2. Department of Psycho-Oncology, National Cancer Center Hospital, Tokyo keshimiz@ncc.go.jp. 3. Graduate School of Clinical Psychology, Teikyo Heisei University, Chiba. 4. Psychiatry Division, Kitasato University Kitasato Institute Hospital, Tokyo. 5. Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital, Tokyo. 6. Department of Hepatobiliary and Pancreatic Surgery, National Cancer Center Hospital, Tokyo. 7. Department of Psycho-Oncology, National Cancer Center Hospital, Tokyo. 8. Department of Neuropsychiatry, Okayama University Hospital, Okayama. 9. Section of Medical Research for Suicide, Center for Suicide Prevention, National Institute of Mental Health, National Center for Neurology & Psychiatry, Tokyo. 10. Division of Palliative Care and Psycho-oncology, Nagoya City University Hospital, Aichi Department of Psychiatry and Cognitive-Behavioral Medicine, Nagoya City University Graduate School of Medical Sciences, Aichi. 11. Innovation Center for Supportive, Palliative and Psychosocial Care, National Cancer Center, Tokyo, Japan.
Abstract
OBJECTIVE: It is known that depression and anxiety occur more frequently in pancreatic cancer patients than in those with other malignancies. However, few studies have assessed depression and anxiety using reliable psychiatric diagnostic tools. The purpose of this study was to determine the prevalence of depression and anxiety among pancreatic cancer patients before and 1 month after the start of anticancer treatment using reliable psychiatric diagnostic tools, and to identify factors that predict their occurrence. METHODS: Pancreatic cancer patients were consecutively recruited. Structured clinical interviews were used to determine the presence of affective disorders, anxiety disorders and adjustment disorders. Baseline interviews were performed prior to initiation of anticancer treatment, while follow-up interviews were performed 1 month after treatment was started. Medical, demographic and psychosocial backgrounds were also assessed as predictive factors. RESULTS: One hundred and ten patients participated in the baseline interview and 91 in the follow-up interview. Depression and anxiety were observed in 15 patients (13.6%) at the baseline, and 15 patients (16.5%) at the follow-up. Lack of confidants was associated with depression and anxiety at the baseline. At the baseline, sadness, lower Karnofsky Performance Status and prior experience with the death of a family member due to cancer predicted newly diagnosed depression and anxiety at the follow-up. CONCLUSION: A considerable percentage of pancreatic cancer patients experienced depression and anxiety. Multidimensional psychosocial predictive factors were found and optimal psychological care should incorporate early detection of sadness.
OBJECTIVE: It is known that depression and anxiety occur more frequently in pancreatic cancerpatients than in those with other malignancies. However, few studies have assessed depression and anxiety using reliable psychiatric diagnostic tools. The purpose of this study was to determine the prevalence of depression and anxiety among pancreatic cancerpatients before and 1 month after the start of anticancer treatment using reliable psychiatric diagnostic tools, and to identify factors that predict their occurrence. METHODS:Pancreatic cancerpatients were consecutively recruited. Structured clinical interviews were used to determine the presence of affective disorders, anxiety disorders and adjustment disorders. Baseline interviews were performed prior to initiation of anticancer treatment, while follow-up interviews were performed 1 month after treatment was started. Medical, demographic and psychosocial backgrounds were also assessed as predictive factors. RESULTS: One hundred and ten patients participated in the baseline interview and 91 in the follow-up interview. Depression and anxiety were observed in 15 patients (13.6%) at the baseline, and 15 patients (16.5%) at the follow-up. Lack of confidants was associated with depression and anxiety at the baseline. At the baseline, sadness, lower Karnofsky Performance Status and prior experience with the death of a family member due to cancer predicted newly diagnosed depression and anxiety at the follow-up. CONCLUSION: A considerable percentage of pancreatic cancerpatients experienced depression and anxiety. Multidimensional psychosocial predictive factors were found and optimal psychological care should incorporate early detection of sadness.
Authors: P Hammel; H L Kindler; M Reni; E Van Cutsem; T Macarulla; M J Hall; J O Park; D Hochhauser; D Arnold; D-Y Oh; A Reinacher-Schick; G Tortora; H Algül; E M O'Reilly; D McGuinness; K Y Cui; S Joo; H K Yoo; N Patel; T Golan Journal: Ann Oncol Date: 2019-12-01 Impact factor: 32.976
Authors: Hao Luo; Daniel A Galvão; Robert U Newton; Pedro Lopez; Colin Tang; Ciaran M Fairman; Nigel Spry; Dennis R Taaffe Journal: Pancreas Date: 2021-03-01 Impact factor: 3.243